Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
Silvia Romero-Murillo, Irene Peris, Anna Maria Lucianò, Nerea Marcotegui, Carmen Vicente, Brian Tran, Kelsey Barrie, Caitlin M. O’Connor, Andrea Torres-López, Maria C. Mateos, Maria L. Cayuela, Victoriano Mulero, Joaquín Fernández-Irigoyen, Enrique Santamaría, Maria D. Odero, Goutham Narla
Silvia Romero-Murillo, Irene Peris, Anna Maria Lucianò, Nerea Marcotegui, Carmen Vicente, Brian Tran, Kelsey Barrie, Caitlin M. O’Connor, Andrea Torres-López, Maria C. Mateos, Maria L. Cayuela, Victoriano Mulero, Joaquín Fernández-Irigoyen, Enrique Santamaría, Maria D. Odero, Goutham Narla
View: Text | PDF
Research Article Cell biology Hematology

Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML

  • Text
  • PDF
Abstract

Cell metabolic rewiring is associated with resistance to venetoclax-azacitidine (Ven-Aza) combination therapy and relapse in patients with acute myeloid leukemia (AML). Drug-resistant cells exhibit an enhanced reliance on oxidative phosphorylation (OXPHOS) for energy production. Therefore, impairing mitochondrial metabolism represents an exciting strategy to face this unmet clinical need. We recently demonstrated that the specific activation of the phosphatase PP2A-B56α enhances the proapoptotic efficacy of venetoclax in AML. Here, through leveraging unbiased multi-omics–based approaches and using both genetic and pharmacological tools, we define key roles for the tumor suppressor PP2A-B56α complex in OXPHOS regulation and treatment response in disease-relevant AML models. From a translational perspective, the specific stabilization of PP2A-B56α heterocomplex with the potentially novel PP2A molecular glue activator, RPT04402, reduces OXPHOS levels in treatment-resistant AML cells and improves treatment response in both Ven-Aza–sensitive and –resistant AML cell lines, primary cells, and in vivo models. Together, our work supports further research on targeted combination therapy approaches based on PP2A-B56α stabilization to counteract OXPHOS-related treatment resistance and improve AML responses in a patient population with historically poor outcomes.

Authors

Silvia Romero-Murillo, Irene Peris, Anna Maria Lucianò, Nerea Marcotegui, Carmen Vicente, Brian Tran, Kelsey Barrie, Caitlin M. O’Connor, Andrea Torres-López, Maria C. Mateos, Maria L. Cayuela, Victoriano Mulero, Joaquín Fernández-Irigoyen, Enrique Santamaría, Maria D. Odero, Goutham Narla

×

Figure 2

Transcriptomics and proteomics analyses indicate that OXPHOS is upregulated in HL-60 B56α–/– models.

Options: View larger image (or click on image) Download as PowerPoint
Transcriptomics and proteomics analyses indicate that OXPHOS is upregula...
(A) Heatmap representation of genes differentially upregulated (red) and downregulated (blue) at transcriptional level in HL-60 B56α–/– clones compared with B56αWT cells (n = ~3 per subline). (B) Hallmark gene-set enrichment analysis of differential gene expression in B56α–/– clones. Positive normalized enrichment score (NES) represents upregulated hallmark gene sets, while negative NES indicates the gene sets downregulated with P < 0.05. (C) Enrichment plot of upregulated OXPHOS hallmark gene set with its NES and false discovery rate (FDR) in B56α–/– clones compared with B56αWT cells. (D) Heatmap representation of proteomics analyses in HL-60 B56α–/– clones compared with B56αWT cells (n = 4 per subline). (E) Hallmark gene set pathways altered in B56α–/– clones compared with B56αWT cells. Hallmarks in purple represent metabolism-related pathways. Statistical significance is expressed as –Log10(P value). (F) Heatmap representation of the differential expression of the mitochondrial proteins from the ETC complex in HL-60 B56αWT and B56α–/– clones (n = 4 per subline). (G) Dynamic representation of oxygen consumption rate (OCR) in HL-60 B56αWT, B56α–/–, and reconstituted B56α clones at basal conditions obtained from 3 biological replicates. (Right) Comparison of the basal respiration, ATP production, maximal respiratory capacity, proton leak, and spare respiratory capacity of the clones expressed as fold change of the normalized HL-60 B56αWT clone values. Data represent mean ± SD and were analyzed by 2-way ANOVA and Tukey post hoc test. (H) Bar graph show average ± SD mitochondrial complex I activity of HL-60 clones measured as the change in absorbance per minute per amount of protein loaded and expressed as the fold change of HL-60 B56αWT clone values. These results were obtained from 3 biological replicates. Statistical significance was determined by 1-way ANOVA and Tukey post hoc test analyses.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts